即時分子診斷全球市場規模、佔有率、趨勢和成長分析報告（2026-2034）

全球即時分子診斷市場預計將從2025年的92.5億美元成長至2034年的166.9億美元，2026年至2034年的複合年成長率（CAGR）為6.78%。隨著醫療專業人員在患者照護環境中對快速、準確的診斷解決方案的需求日益成長，該市場正經歷強勁成長。即時分子診斷無需依賴中心檢查室檢測，即可快速檢測感染疾病、遺傳性疾病和其他疾病。對疾病早期診斷的需求不斷成長、醫療保健覆蓋範圍的擴大以及預防醫學意識提升，都在推動這些先進診斷技術的應用。

分子生物學、攜帶式診斷設備和核酸檢測技術的進步正在提高檢測速度、靈敏度和準確性。醫療機構正在採用能夠提供及時臨床結果的緊湊型診斷平台，從而支持快速制定治療決策並改善患者預後。對感染疾病監測、個人化醫療和分散式醫療服務投入的增加，為市場創造了有利環境。與數位醫療系統的整合進一步提升了臨床效率。

隨著醫療系統持續將快速診斷和個人化護理置於優先地位，前景一片光明。人工智慧、自動化檢體處理和連網診斷平台將提升營運效率並拓展檢測能力。急診醫學、居家醫療和遠端醫療服務日益成長的需求將創造巨大的發展機會。持續的技術創新將進一步鞏固即時分子診斷在現代醫學中的作用。

我們的報告經過精心撰寫，旨在提供涵蓋廣泛行業和市場的全面且切實可行的洞察。每份報告都包含幾個關鍵組成部分，旨在幫助您全面了解市場環境：

市場概覽：本節對市場進行了清晰的說明，包括關鍵定義、分類以及當前行業格局的概述。

市場動態：對影響市場成長的主要促進因素、限制因素、機會和挑戰進行詳細評估。這包括技術發展、法律規範和不斷變化的行業趨勢等因素。

市場區隔分析：本部分根據產品類型、應用、最終用戶和地區將市場系統性地分類為若干關鍵細分市場。本部分揭示了每個細分市場的表現、成長潛力和市場貢獻。

競爭格局：我們對主要市場參與企業進行了詳細評估，包括其市場定位、產品系列、策略舉措和財務表現。這有助於深入了解競爭趨勢和主要參與者所採取的策略。

市場預測：本部分提供基於數據的市場規模和成長模式預測，預測期為指定時期。它綜合考慮了歷史趨勢、當前市場狀況和定量分析，以識別預期的未來趨勢。

區域分析：這包括對主要地理區域的市場表現進行全面檢驗，確定高成長領域和區域趨勢，以更深入地了解每個區域特有的市場機會。

新趨勢與新機會：識別關鍵市場趨勢、技術進步和新興投資機會。本部分重點在於潛在成長領域和未來產業趨勢。

客製化選項：我們提供靈活的報告客製化服務，以滿足您的特定需求。這包括額外的細分、國家/地區分析、競爭對手分析、客製化資料點或針對特定細分市場的洞察，從而更有效地支援您的策略決策。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章 全球即時分子診斷市場：依技術分類

• 市場分析、洞察與預測
• 基於PCR的
• 基因定序基礎
• 雜合反應方法
• 基於微陣列

第5章 全球即時分子診斷市場：依應用分類

• 市場分析、洞察與預測
• 感染疾病（HIV POC、困難梭狀桿菌POC、HBV POC、肺炎或鏈球菌相關感染疾病、呼吸道融合細胞病毒(RSV) POC、HPV POC、流感 POC、HCV POC、MRSA POC、結核病及抗藥性結核病 POC、HSV POC 以及其他感染疾病）
• 腫瘤學
• 血液學
• 產前檢查
• 內分泌學
• 其他用途

第6章 全球即時分子診斷市場：依檢測地點分類

• 市場分析、洞察與預測
• OTC
• POC

第7章 全球即時分子診斷市場：依最終用途分類

• 市場分析、洞察與預測
• 分散式檢查實驗室
• 醫院
• 居家照護
• 輔助生活醫療機構
• 其他

第8章 全球即時分子診斷市場：按地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第9章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第10章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • F. Hoffmann-La Roche
  • Abbott
  • QIAGEN
  • Danaher Corporation
  • BioMerieux
  • OraSure Technologies
  • Binx Health
  • QuidelOrtho
  • Cepheid
  • Siemens Healthineers
  • Thermo Fisher Scientific
  • Bio-Rad Laboratories
  • Hologic
  • SEKISUI Diagnostics
  • Bosch Healthcare Solutions
  • Trivitron Healthcare
  • Meridian Bioscience
  • GenMark Diagnostics
  • Mesa Biotech
  • Molbio Diagnostics

The global point-of-care molecular diagnostics market size is expected to reach USD 16.69 Billion in 2034 from USD 9.25 Billion in 2025, growing at a CAGR of 6.78 during 2026-2034.This market is experiencing robust growth as healthcare providers increasingly require rapid and accurate diagnostic solutions at the point of patient care. Point-of-care molecular diagnostics enable quick detection of infectious diseases, genetic conditions, and other medical disorders without relying on centralized laboratory testing. Rising demand for early disease diagnosis, expanding healthcare accessibility, and increasing awareness of preventive healthcare are driving widespread adoption of these advanced diagnostic technologies.

Advancements in molecular biology, portable diagnostic devices, and nucleic acid testing technologies are improving testing speed, sensitivity, and accuracy. Healthcare facilities are adopting compact diagnostic platforms that provide timely clinical results, supporting faster treatment decisions and improved patient outcomes. Growing investments in infectious disease surveillance, personalized medicine, and decentralized healthcare services are creating favorable market conditions. Integration with digital healthcare systems is further enhancing clinical efficiency.

The future outlook remains highly encouraging as healthcare systems continue prioritizing rapid diagnostics and personalized patient care. Artificial intelligence, automated sample processing, and connected diagnostic platforms will improve operational efficiency and expand testing capabilities. Rising demand from emergency care, home healthcare, and remote medical services will generate significant growth opportunities. Continuous technological innovation will strengthen the role of point-of-care molecular diagnostics in modern healthcare.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Technology

• PCR-based
• Genetic Sequencing-based
• Hybridization-based
• Microarray-based

By Application

• Infectious Diseases (HIV POC, Clostridioides difficile POC, HBV POC, Pneumonia or Streptococcus-Associated Infections, Respiratory Syncytial Virus (RSV) POC, HPV POC, Influenza/Flu POC, HCV POC, MRSA POC, TB and Drug-Resistant TB POC, HSV POC, Other Infectious Diseases)
• Oncology
• Hematology
• Prenatal Testing
• Endocrinology
• Other Applications

By Test Location

• OTC
• POC

By End Use

• Decentralized Labs
• Hospitals
• Home Care
• Assisted Living Healthcare Facilities
• Others

COMPANIES PROFILED

• F. Hoffmann-La Roche, Abbott, QIAGEN, Danaher Corporation, bioMerieux, OraSure Technologies, binx health, QuidelOrtho, Cepheid, Siemens Healthineers, Thermo Fisher Scientific, Bio-Rad Laboratories, Hologic, SEKISUI Diagnostics, Bosch Healthcare Solutions, Trivitron Healthcare, Meridian Bioscience, GenMark Diagnostics, Mesa Biotech, Molbio Diagnostics

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET: BY TECHNOLOGY 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Technology
• 4.2. PCR-based Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Genetic Sequencing-based Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Hybridization-based Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Microarray-based Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET: BY APPLICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Application
• 5.2. Infectious Diseases (HIV POC, Clostridioides difficile POC, HBV POC, Pneumonia or Streptococcus-Associated Infections, Respiratory Syncytial Virus (RSV) POC, HPV POC, Influenza/Flu POC, HCV POC, MRSA POC, TB and Drug-Resistant TB POC, HSV POC, Other Infectious Diseases) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Oncology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Hematology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Prenatal Testing Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Endocrinology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.7. Other Applications Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET: BY TEST LOCATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Test Location
• 6.2. OTC Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. POC Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET: BY END USE 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast End Use
• 7.2. Decentralized Labs Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Home Care Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.5. Assisted Living Healthcare Facilities Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET: BY REGION 2022-2034 (USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Technology
  • 8.2.2 By Application
  • 8.2.3 By Test Location
  • 8.2.4 By End Use
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Technology
  • 8.3.2 By Application
  • 8.3.3 By Test Location
  • 8.3.4 By End Use
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Technology
  • 8.4.2 By Application
  • 8.4.3 By Test Location
  • 8.4.4 By End Use
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Technology
  • 8.5.2 By Application
  • 8.5.3 By Test Location
  • 8.5.4 By End Use
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Technology
  • 8.6.2 By Application
  • 8.6.3 By Test Location
  • 8.6.4 By End Use
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL POINT-OF-CARE MOLECULAR DIAGNOSTICS INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 F. Hoffmann-La Roche
  • 10.2.2 Abbott
  • 10.2.3 QIAGEN
  • 10.2.4 Danaher Corporation
  • 10.2.5 BioMerieux
  • 10.2.6 OraSure Technologies
  • 10.2.7 Binx Health
  • 10.2.8 QuidelOrtho
  • 10.2.9 Cepheid
  • 10.2.10 Siemens Healthineers
  • 10.2.11 Thermo Fisher Scientific
  • 10.2.12 Bio-Rad Laboratories
  • 10.2.13 Hologic
  • 10.2.14 SEKISUI Diagnostics
  • 10.2.15 Bosch Healthcare Solutions
  • 10.2.16 Trivitron Healthcare
  • 10.2.17 Meridian Bioscience
  • 10.2.18 GenMark Diagnostics
  • 10.2.19 Mesa Biotech
  • 10.2.20 Molbio Diagnostics